Awakn Life Sciences Corp.


Streetwise Company Fact Sheet

Awakn Life Sciences Corp.


2023/3/29 4:10:19

Analyst coverage

Maxim GroupJason McCarthy
StifelAndrew Partheniou
Canaccord GenuityMatthew Pepler
H.C. Wainwright & Co.Patrick Trucchio
H.C. Wainwright & Co.Patrick Trucchio

Newsletter coverage

Company News

View Latest News

Streetwise Reports Articles

02/28/2023 - View Article
02/09/2023 - View Article
02/07/2023 - View Article
01/25/2023 - View Article
01/24/2023 - View Article

Streetwise - Awakn Life Sciences Corp. Ownership Overview*

Awakn Life Sciences Corp. (AWKN:NEO; AWKNF:OTCQB)

*Share Structure as of 1/24/2023

Company News 

2/28/2023 – Awakn Life Sciences Signs Its Fourth Licensing Partnership Agreement in North America, and First in California

2/21/2023 – Awakn Life Sciences Signs Its First Licensing Partnership Agreement in Europe

2/14/2023 – Awakn Life Sciences Announces the Opening of Its Fourth Clinic

2/9/2023 – Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology

2/8/2023 – Awakn Life Sciences Responds to OTC Markets Request on Recent Promotional Activity

2/7/2023 – Awakn Life Sciences Granted Fast-Track Designation from UK Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder

1/24/2023 – Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect